Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Raytheon Technologies Corp (RTX) vs Vir Biotechnology Inc. Common Stock (VIR) Price & Performance

Raytheon Technologies CorpTrade
Vir Biotechnology Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

Raytheon Technologies Corp vs Vir Biotechnology Inc. Common Stock — how do they compare? Raytheon Technologies Corp trades at $187.4 (market cap $246.67B), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.80B). The key difference: Raytheon Technologies Corp is far larger — about 137× Vir Biotechnology Inc. Common Stock's market cap, and Raytheon Technologies Corp pays a 1.6% dividend while Vir Biotechnology Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Raytheon Technologies Corp for 78 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.

RTXVIR
Market Cap
$246.67B$1.80B
Volume
4,726,7141,782,836
Sector
IndustrialsHealth
52-Week High
$225.49$11.78
52-Week Low
$157.00$5.12
Typical Hold Time
78 Days0 Days
Enterprise Value
$277.22B$1.36B
Dividend Yield
1.6%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Raytheon Technologies Corp

RTX trades at $186.66, up 0.37% on the day, with a bearish technical signal but strong fundamental momentum. The company reported revenue of $88.60 billion in 2025, with net income of $6.73 billion and a profit margin of 7.59%. Recent earnings beats and a $289 billion backlog highlight robust demand in aerospace and defense. Analyst consensus is bullish with a $233.55 price target, though technical indicators show near-term resistance.

The outlook for RTX is positive, driven by sustained defense spending and commercial aviation recovery. Investment opportunities include earnings growth and dividend yield, while risks involve execution on the large backlog and potential defense budget fluctuations. The stock offers value if it can maintain its growth trajectory amid geopolitical tailwinds.

Vir Biotechnology Inc. Common Stock

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

RTX
2% Buy98% Sell
Avg holding period · 78 Days
VIR
51% Buy49% Sell
Avg holding period · 0 Days

Top news

Latest headlines on both assets

About Raytheon Technologies Corp

Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.

Read more on RTX →

About Vir Biotechnology Inc. Common Stock

Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.

Read more on VIR →